A pilot, double blind randomised controlled trial of prednisolone for women with recurrent miscarriage and raised uterine natural killer cell density [Abstract]
Tang, Ai-Wei, Alfirevic, Zarko, Turner, M. A., Drury, J., Topping, J., Dawood, Feroza, Farquharson, Roy G. and Quenby, Siobhan. (2011) A pilot, double blind randomised controlled trial of prednisolone for women with recurrent miscarriage and raised uterine natural killer cell density [Abstract]. Human Reproduction, Vol.26 (Suppl.1). i48-i50. ISSN 0268-1161Full text not available from this repository.
Official URL: http://dx.doi.org/10.1093/humrep/26.s1.34
Introduction: Multiple trials of immunotherapy for reproductive failure have failed to demonstrate significant benefit. A reason for this may be the lack of a test that selects which women will benefit from treatment. High density of uterine naturak killer (uNK) cells has been associated with recurrent miscarriage (RM) and prednisolone was shown to reduce this uNK cell density. Hence we carried out a double blind randomised placebo controlled trial of prednisolone versus placebo in early pregnancy for women with RM and increased uNK cell density. The aim of this pilot trial was to assess the feasibility of recruitment, integrity of trial procedures and potential efficacy for future power calculations.
|Item Type:||Journal Article|
|Subjects:||Q Science > QR Microbiology > QR180 Immunology
R Medicine > RG Gynecology and obstetrics
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Library of Congress Subject Headings (LCSH):||Infertility -- Immunotherapy, Miscarriage -- Treatment, Clinical trials, Killer cells, Uterus -- Immunology, Pregnancy -- Immunology|
|Journal or Publication Title:||Human Reproduction|
|Access rights to Published version:||Restricted or Subscription Access|
|Description:||Journal supplement: Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology, Stockholm, Sweden, 3-6 July 2011|
Actions (login required)